Michael Pellini has just joined Bill Maris at Section 32 — focused on patient care and drug development
Michael Pellini has just jumped into a senior role at one of the most intriguing new venture funds in the biopharma/healthcare world. The former CEO — and current chairman — at Foundation Medicine $FMI, which just won approval for a new diagnostic tool for solid tumors, has joined Bill Maris as a managing partner at Section 32.
Here’s his message to me:
Really excited to team up with Bill Maris and Jenn Kercher (ex-GV). Broad mandate but I’ll primarily be focused on opportunities at intersection of health care and technology which can have a significant impact on patient care and/or drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.